Next generation sequencing of acute myeloid leukemia: influencing prognosis.
Next generation sequencing of acute myeloid leukemia: influencing prognosis.
复制标题
DOI：
10.1186/1471-2164-16-s1-s5
复制
发表时间：
2015
期刊：
影响因子：
4.4
通讯作者：
Ahmed F
中科院分区：
文献类型：
--
作者：
Ilyas AM;Ahmad S;Faheem M;Naseer MI;Kumosani TA;Al-Qahtani MH;Gari M;Ahmed F
急性髓性白血病（acute myeloid leukemia，AML）是一种造血细胞克隆性疾病，其特征是骨髓和外周血中未成熟母细胞的积聚。作为一种异质性疾病，AML一直是众多研究的主题，这些研究专注于阐明临床，细胞和分子变异，旨在更好地理解和治疗该疾病。AML的细胞遗传学风险分层已得到很好的建立，临床医生通常将其用于染色体异常病例的治疗管理。在过去的十年中，新的分子异常的连续纳入大大改变了AML的分类和理解。随着下一代测序（NGS）技术的出现，新的分子异常的发现已经加速。NGS已成功用于多项研究，并提供了AML分子畸变以及潜在克隆进化的前所未有的概述。NGS发现的异常扩展谱目前正在广泛验证其预后和治疗价值。在这篇综述中，我们强调了在NGS时代AML的理解的最新进展。
Acute myeloid leukemia (AML) is a clonal disorder of the blood forming cells characterized by accumulation of immature blast cells in the bone marrow and peripheral blood. Being a heterogeneous disease, AML has been the subject of numerous studies that focus on unraveling the clinical, cellular and molecular variations with the aim to better understand and treat the disease. Cytogenetic-risk stratification of AML is well established and commonly used by clinicians in therapeutic management of cases with chromosomal abnormalities. Successive inclusion of novel molecular abnormalities has substantially modified the classification and understanding of AML in the past decade. With the advent of next generation sequencing (NGS) technologies the discovery of novel molecular abnormalities has accelerated. NGS has been successfully used in several studies and has provided an unprecedented overview of molecular aberrations as well as the underlying clonal evolution in AML. The extended spectrum of abnormalities discovered by NGS is currently under extensive validation for their prognostic and therapeutic values. In this review we highlight the recent advances in the understanding of AML in the NGS era.